GlassScriptPhysician profile
Chrystal M Killinger
NPI 1609267731
$7,165.50
in general payments reported to CMS, 2019-2025
20 companies · $1,978 in 2025
The $1,978 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $397 · 2022: $1,222 · 2023: $1,799 · 2024: $1,770 · 2025: $1,978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,546.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,670.37 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $922.94 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $720.51 | 2021-2025 | |
| Janssen Biotech, INC. | $692.05 | 2023-2025 | Stelara, Tremfya, Simponi |
| Celgene Corporation | $478.10 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $279.86 | 2023-2025 | Xifaxan, Relistor |
| Intercept Pharmaceuticals, INC. | $238.83 | 2022-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $231.17 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $195.03 | 2023-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $152.21 | 2024-2025 | Iqirvo |
| Pfizer INC. | $122.92 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $101.74 | 2024 | Zeposia |
| Madrigal Pharmaceuticals | $73.02 | 2025 | Rezdiffra |
| Fresenius Kabi USA, LLC | $64.97 | 2023-2024 | Idacio |
| Ardelyx, INC. | $59.55 | 2024-2025 | Ibsrela |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $58.76 | 2025 | |
| Ironwood Pharmaceuticals, INC | $37.06 | 2024 | |
| Phathom Pharmaceuticals, INC. | $27.90 | 2025 | Voquezna |
| Celltrion USA INC. | $20.31 | 2025 | Vegzelma |
| Aimmune Therapeutics, INC. | $18.20 | 2025 | Vowst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chrystal Killinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.